| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, See Remarks And Footnotes | Director, 10% Owner | 10% Owner +5 more
17 companies
Bvf Partners L P/il is a Director, 10% Owner at MLTX, with reported holdings spanning 17 companies. Recent filings cover 221 purchases and 35 sales. Those positions are worth an estimated $472.0M at current prices.
Our model assigns Bvf Partners L P/il a middling insider score of 60/100, based on 45 past trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of +9.3%.
Bvf Partners L P/il's largest disclosed position is in KYMR as Director, See Remarks And Footnotes, worth about $208.8M. Net of sales, the recent Form 4 record there shows accumulation of 1,183,914 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | KYMR Kymera Therapeutics, Inc. | Director, See Remarks And Footnotes | Sell | 1,630,658 | $106.50 | $173,665,077.00 | -95.4% | +7.1% | - | |
| Mar 31, 2026 | MLTX Moonlake Immunotherapeutics | Director, 10% Owner | Sell | 3,750,000 | $16.79 | $62,962,500.00 | -78.3% | +6.8% | - | |
| Jun 30, 2025 | KYMR Kymera Therapeutics, Inc. | Director, See Remarks And Footnotes | Buy | 317,167 | $44.00 | $13,955,348.00 | +875.1% | +34.1% | +162.8% | |
| May 16, 2025 | XOMA Xoma Royalty Corp | 10% Owner | Sell | 392,723 | $27.10 | $10,642,793.30 | -23.7% | +17.0% | +54.7% | |
| Jan 24, 2025 | XOMA Xoma Royalty Corp | 10% Owner | Sell | 650,717 | $26.10 | $16,983,713.70 | -100% | -9.3% | 0.0% | |
| Oct 4, 2024 | MLTX Moonlake Immunotherapeutics | Director, 10% Owner | Sell | 2,000,000 | $50.00 | $100,003,200.00 | -60.8% | -3.1% | -84.8% | |
| May 9, 2024 | ELDN Eledon Pharmaceuticals, Inc. | 10% Owner | Buy | 1,927,937 | $0.00 | - | -112.9% | +8.3% | +20.4% | |
| Nov 16, 2023 | RPTX Repare Therapeutics Inc. | 10% Owner | Buy | 1,227,301 | $5.09 | $6,249,889.20 | -180.9% | +22.5% | -44.1% | |
| Nov 3, 2023 | KYMR Kymera Therapeutics, Inc. | Director, See Remarks And Footnotes | Buy | 414,105 | $12.80 | $5,301,325.49 | -346.6% | +129.0% | +225.6% | |
| Nov 2, 2023 | RPTX Repare Therapeutics Inc. | 10% Owner | Buy | 783,709 | $3.60 | $2,821,352.40 | -262.4% | +80.7% | -1.1% |